Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-operative Zoledronate in Triple Negative Breast Cancer
NCT02347163Phase 2Terminated
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Feb 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoledronate in triple-negative breast cancer (TNBC), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoint: Proportion of responder patients (>=30% reduction in Ki67) at 7 days. Started Feb 2015; status: terminated.
02
Drugs
zoledronate
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02347163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02347163.